Abstract: ω6-polyunsaturated fatty acid (PUFA) metabolites represented by arachidonic acid promote inflammation, while, ω3-PUFAs represented by eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are known to exhibit anti-inflammator y ef fects. However, the mechanisms of anti-inflammator y ef fects by ω3-PUFA have been unknown for a long time. Recent progress of lipid analytical techniques allow the identification of ω3-PUFA-derived lipid mediators such as resolvins, protectins, and maresins with pro-resolution and anti-inflammator y activities. We recently identified 17,18-epoxyeicosatetraenoic acid (17,18-EpETE) as a new class of EPA metabolites, which has anti-allergic and antiinflammator y ef fect. The anti-inflammator y ef fects were mediated by inhibiting neutrophil migration in G protein-coupled receptor (GPR) 40-dependent manner. Accumulating evidence has revealed that ω3-PUFAs af fect the intestinal bacteria, and consequently regulate immune systems. In this review, we introduce the development and control of allergic and inflammator y diseases via changes in lipid metabolites and intestinal bacteria initiated by dietar y oils. 
